ONCOLOGY RESEARCH AND TREATMENT Journal
Overview
publication venue for
- Mobocertinib (TAK-788) in metastatic EGFR Exon 20 Insertions (ex20ins) + NSCLC: Results of platinum-experienced Patients and the EXCLAIM Cohort of a Phase 1/2 Study 2022
- IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups 2018
- Primary PFS and safety analyses of a randomized Phase III study of carboplatin plus paclitaxel plus /- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150) 2018
- A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avasting (C) 2017
- Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR-Expressing Squamous Non-Small-Cell Lung Cancer German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE). 39:539-547. 2016
Research
category
- ONCOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 2296-5270
Electronic International Standard Serial Number (EISSN)
- 2296-5262
Other
journal abbreviation
- ONCOL RES TREAT